Published in Clin Orthop Relat Res on August 31, 2010
Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int (2011) 2.49
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab (2012) 1.18
Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res (2012) 1.15
Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Skeletal Radiol (2012) 0.87
Do bisphosphonates cause femoral insufficiency fractures? J Orthop Traumatol (2012) 0.87
Stress fractures in elderly patients. Int Orthop (2012) 0.85
Atypical femur fractures: a review of the evidence and its implication to clinical practice. Ther Adv Musculoskelet Dis (2011) 0.83
Prodromal Symptoms in Patients with Bisphosphonate-Associated Atypical Fractures of the Femur. J Bone Miner Metab (2014) 0.79
Bisphosphonate-associated peri-implant fractures: a new clinical entity? A series of 10 patients with 11 fractures. Acta Orthop (2015) 0.78
The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue. Bone Rep (2015) 0.78
Atypical femoral fractures in association with bisphosphonate therapy: a case series. Emerg Radiol (2014) 0.76
Simultaneous, bilateral, complete atypical femoral fractures after long-term alendronate use. J Orthop (2016) 0.75
Association between alendronate and atypical femur fractures: a meta-analysis. Endocr Connect (2014) 0.75
A case of bilateral stress fractures in an old woman: three years of pain. Clin Cases Miner Bone Metab (2014) 0.75
Caveats of bisphosphonate abuse. Indian J Orthop (2016) 0.75
Progression of bisphosphonate-associated impending atypical femoral fracture despite prophylactic cephalomedullary nailing: A case report and review of literature. J Clin Orthop Trauma (2016) 0.75
Bisphosphonate-induced atypical subtrochanteric femoral fracture. BMJ Case Rep (2013) 0.75
We need a break: Bisphosphonates. J Clin Orthop Trauma (2013) 0.75
Successful conservative treatment: multiple atypical fractures in osteoporotic patients after bisphosphate medication: a unique case report. Medicine (Baltimore) (2015) 0.75
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk (2012) 0.75
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
Bisphosphonate-induced osteopetrosis. N Engl J Med (2003) 4.99
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med (1992) 4.19
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br (2007) 4.10
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res (2000) 3.86
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int (2008) 3.80
Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma (2008) 3.74
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 3.65
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury (2008) 3.50
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int (2010) 2.69
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med (2000) 2.46
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (2000) 2.24
Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am (2009) 2.19
Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev (2006) 2.08
Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab (2008) 1.99
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone (2001) 1.94
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res (2004) 1.93
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int (2008) 1.85
Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci (1984) 1.79
Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res (2007) 1.76
Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med (1995) 1.72
Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res (2009) 1.55
Design of the Fracture Intervention Trial. Osteoporos Int (1993) 1.53
Long-term safety of bisphosphonates. J Clin Endocrinol Metab (2005) 1.50
Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma (2010) 1.50
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics (2009) 1.45
Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res (2004) 1.42
Aging of microstructural compartments in human compact bone. J Bone Miner Res (2003) 1.41
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int (2001) 1.36
Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res (2003) 1.31
Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res (2002) 1.30
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int (2008) 1.24
Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report. Acta Orthop (2008) 1.24
Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone (2003) 1.23
Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics (2006) 1.22
Influence of remodeling on the mineralization of bone tissue. Osteoporos Int (2009) 1.07
Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone (2000) 1.05
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med (1997) 1.04
Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res (2009) 1.00
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int (2004) 1.00
Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone (2010) 1.00
Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res (1994) 0.94
Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int (2009) 0.93
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin (2006) 0.92
Bisphosphonate-induced fractures: nature strikes back? Acta Orthop (2008) 0.91
Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int (2009) 0.91
Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab (2006) 0.85
Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Expert Opin Drug Metab Toxicol (2008) 0.84
Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res (2009) 0.83
The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol (2002) 0.81
Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy. Rheumatol Int (2010) 0.80
Prophylactic bilateral intramedullary femoral nails for bisphosphonate-associated signs of impending subtrochanteric hip fracture. Orthopedics (2010) 0.80
Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics (2010) 0.76
CONSORT compliance in surgical randomized trials: are we there yet? A systematic review. Ann Surg (2013) 2.12
Arthroscopy to treat osteoarthritis of the knee? Med J Aust (2012) 1.97
A randomised clinical trial evaluating the efficacy of physiotherapy after rotator cuff repair. Aust J Physiother (2004) 1.60
Tourniquet application only during cement fixation in total knee arthroplasty: a double-blind, randomized controlled trial. ANZ J Surg (2012) 1.55
Nonoperative versus operative treatment for thoracolumbar burst fractures without neurologic deficit: a meta-analysis. Clin Orthop Relat Res (2011) 1.33
Reliability of 3 methods for assessing shoulder strength. J Shoulder Elbow Surg (2002) 1.31
Delay to surgery and mortality after hip fracture. ANZ J Surg (2007) 1.30
Cryotherapy following total knee replacement. Cochrane Database Syst Rev (2012) 1.21
Understanding the effect of compensation on recovery from severe motor vehicle crash injuries: a qualitative study. Inj Prev (2010) 1.11
Advances and future directions for management of trauma patients with musculoskeletal injuries. Lancet (2012) 1.11
Using magnetic resonance imaging to predict adequate graft diameters for autologous hamstring double-bundle anterior cruciate ligament reconstruction. Arthroscopy (2011) 1.00
Cryotherapy after total knee arthroplasty a systematic review and meta-analysis of randomized controlled trials. J Arthroplasty (2009) 1.00
Is discharge knee range of motion a useful and relevant clinical indicator after total knee replacement? Part 2. J Eval Clin Pract (2011) 0.93
Validity and reliability of using photography for measuring knee range of motion: a methodological study. BMC Musculoskelet Disord (2011) 0.93
Burnout in orthopaedic surgeons: a review. ANZ J Surg (2013) 0.92
Do Psychological Factors Predict Poor Outcome in Patients Undergoing TKA? A Systematic Review. Clin Orthop Relat Res (2015) 0.91
Rotator cuff repair with bioabsorbable screws: An in vivo and ex vivo investigation. Arthroscopy (2003) 0.89
Satisfaction with joint replacement in public versus private hospitals: a cohort study. ANZ J Surg (2012) 0.86
Pulsed electromagnetic field stimulation for acute tibial shaft fractures: a multicenter, double-blind, randomized trial. J Bone Joint Surg Am (2011) 0.86
Comparison of tibial bone coverage of 6 knee prostheses: a magnetic resonance imaging study with controlled rotation. J Orthop Surg (Hong Kong) (2012) 0.85
Quality of conduct and reporting of meta-analyses of surgical interventions. Ann Surg (2015) 0.84
Peri-articular steroid injection in total knee arthroplasty: a prospective, double blinded, randomized controlled trial. J Arthroplasty (2012) 0.83
Is discharge knee range of motion a useful and relevant clinical indicator after total knee replacement? Part 1. J Eval Clin Pract (2011) 0.82
Evidence-based review for patients undergoing elective hip and knee replacement. ANZ J Surg (2013) 0.82
Correlation between metal allergy and treatment outcomes after ankle fracture fixation. J Orthop Surg (Hong Kong) (2011) 0.81
Introductory insights into patient preferences for outpatient rehabilitation after knee replacement: implications for practice and future research. J Eval Clin Pract (2011) 0.81
Minimal detectable change for mobility and patient-reported tools in people with osteoarthritis awaiting arthroplasty. BMC Musculoskelet Disord (2014) 0.81
Clinical practice guidelines for the management of acute limb compartment syndrome following trauma. ANZ J Surg (2010) 0.80
Determinants of time to surgery for patients with hip fracture. ANZ J Surg (2014) 0.79
Hospital Inpatient versus HOme-based rehabilitation after knee arthroplasty (The HIHO study): study protocol for a randomized controlled trial. Trials (2013) 0.79
Primum non nocere and randomised placebo-controlled surgical trials: a dilemma? ANZ J Surg (2009) 0.78
Improvements in knee range and symptomatic and functional behavior after knee arthroplasty based on preoperative restriction in range. J Arthroplasty (2011) 0.78
Non-emergency management of hip fractures in older patients. J Orthop Surg (Hong Kong) (2009) 0.78
Can the Oxford Scores be used to monitor symptomatic progression of patients awaiting knee or hip arthroplasty? J Arthroplasty (2013) 0.78
Necrotizing infection due to Bacillus cereus mimicking gas gangrene following penetrating trauma. J Orthop Trauma (2005) 0.78
Patterns of recovery following knee and hip replacement in an Australian cohort. Aust Health Rev (2009) 0.78
Arthroscopy to treat osteoarthritis of the knee? Med J Aust (2013) 0.75
Correction: Randomised Trial Support for Orthopaedic Surgical Procedures. PLoS One (2015) 0.75
Reply to letter: "CONSORT compliance in surgical randomized trials: possible solutions". Ann Surg (2015) 0.75
Aggressive management of tibial osteomyelitis shows good functional outcomes. Eplasty (2011) 0.75
Does access to compensation have an impact on recovery outcomes after injury? Comment. Med J Aust (2010) 0.75
Smoking, quitting and the provision of smoking cessation support: A survey of orthopaedic trauma patients. J Orthop Trauma (2017) 0.75
Trends, Complications, and Costs for Hospital Admission and Surgery for Lumbar Spinal Stenosis. Spine (Phila Pa 1976) (2017) 0.75
The Australian arthroplasty thromboprophylaxis survey. J Arthroplasty (2011) 0.75
Surgical options for lumbar spinal stenosis. Cochrane Database Syst Rev (2016) 0.75